Skip to main content
. 2022 Oct 13;13:6043. doi: 10.1038/s41467-022-33768-x

Fig. 1. Tgfbr2−/− CD8+ T cells exhibited greatly enhanced responses to tumor vaccine.

Fig. 1

a–c Pmel-1 alone. a Schematics; b tumor growth; c survival curve. No T cell transfer group is shown in gray dashed line. Black lines, WT Pmel-1 recipients and red lines, Tgfbr2−/− recipients. For b and c, WT, n = 7, Tgfbr2−/−, n = 8 and no cell group, n = 8. d–f Pmel-1 +tumor vaccine (indicated as a blue arrow). d Schematics; e tumor growth; f Survival curve. For e and f, WT, n = 15, Tgfbr2−/−, n = 8. g–i Pmel-1 + αPD-L1 (indicated as yellow arrows). g Schematics; h tumor growth; i Survival curve. For h and i, WT, n = 10, Tgfbr2−/−, n = 11. j–l Pmel-1+tumor vaccine +  αPD-L1. j Schematics; k tumor growth; l Survival curve. For k and l, WT, n = 10, Tgfbr2−/−, n = 9. 2–3 independent repeats for each setting. Each line in b, e, h and k represents the results from an individual mouse. N.S., not significant (p > 0.05) and indicated p values were calculated by Mantel–Cox test. Two-sided tests were used. Source data are provided as a Source data file.